Pasar al contenido principal

UN TRATAMIENTO MULTIVALENTE EPIGENETICO PARA LAS ENFERMEDADES DE PARKINSON Y ALZHEIMER

PID2022-136530OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE ALCALA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Hydrazides as Inhibitors of Histone Deacetylases

  • Carreiras, Maria do Carmo
  • Marco-Contelles, Jose
In this Perspective, we have brought together available biological evidence on hydrazides as histone deacetylase inhibitors (HDACis) and as a distinct type of Zn-binding group (ZBG) to be reviewed for the first time in the literature. N-Alkyl hydrazides have transformed the field, providing innovative and practical chemical tools for selective and effective inhibition of specific histone deacetylase (HDAC) enzymes, in addition to the usual hydroxamic acid and o-aminoanilide ZBG-bearing HDACis. This has enabled efficient targeting of neurodegenerative diseases such as Alzheimer’s disease, cancer, cardiovascular diseases, and protozoal pathologies., JMC thanks AEI (Government of Spain; Grants PID2019-105813RB-C21 and PID2022-136530OB-I00) for support, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Masupirdine, a Selective Serotonin 5-HT6 Receptor Antagonist for Alzheimer’s Disease

  • Toledano-Pinedo, Mireia
  • Iriepa, Isabel
  • Rodríguez-Fernández, M. Mercedes
  • Marco-Contelles, José
Masupirdine is an oral, small, and safe molecule, readily available by a robust, twostep synthetic scheme, showing a potent, selective serotonin 5-HT 6 receptor antagonist profile, procognitive effects in various behavioral animal models in Phase 3 clinical trials for the treatment of agitation in patients with Alzheimer’s dementia., I.I. and J.M.C. thank AEI (Government of Spain) for support (PID2022-136530OB-I00), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Crosstalk between NLRP3 Signaling and Histone Deacetylases in Inflammasome-Driven Diseases

  • Tan, Kathrin
  • Rodríguez-Fernández, M. Mercedes
  • Keuler, Tim
  • Hansen, Finn K.
  • Gütschow, Michael
  • Weindl, Günther
  • Marco-Contelles, José
The NLRP3 inflammasome is a validated therapeutic target in inflammatory, metabolic, and neurodegenerative diseases. Epigenetic regulators, particularly histone deacetylases (HDACs), have emerged as key modulators of inflammasome priming and activation. Recent advances in medicinal chemistry have provided new chemical modalities for the mechanistic interrogation and the potential therapeutic modulation of NLRP3 signaling. This Perspective dissects the mechanistic interface between HDAC-dependent epigenetic control and NLRP3 signaling and highlights emerging chemical tools, including isoform-selective inhibitors and targeted protein degraders. We discuss the challenges of isoform selectivity, species-specific differences, and the therapeutic potential of HDAC-based strategies to attenuate aberrant NLRP3 activity while minimizing off-target effects. Understanding this epigenetic-inflammasome crosstalk may provide a framework for translating epigenetic modulation into innovative treatments for inflammasome-driven diseases., The work of F.K.H., M.G., and G.W. is funded by the DFG GRK2873 (494832089). J.M.-C thanks AEI (Government of Spain) for support (Grants PID2019-105813RB-C21, PID2022-136530OB-I00, and RED2022-134511-T). M.M.R.F. thanks Ignacio BenitoGómezforhishelpintheanalysisofthe information retrieved by J.M.-C. The TOC graphic and Figures 3 − ■ 5 were created with Biorender.com., Peer reviewed